Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic.
The penetration of roxithromycin (RU 28965), an ether oxime derivative of erythromycin, into the cells and fluid lining the epithelial surface of the lower respiratory tract was studied by performing fiber-optic bronchoscopy with bronchoalveolar lavage on eight patients who had received roxithromycin at 300 mg perorally every 12 h for 5 days. The apparent volume of epithelial lining fluid recovered by bronchoalveolar lavage was determined by using urea as an endogenous marker. There was a significant relationship (r = 0.75; P less than 0.02) between roxithromycin levels in plasma and epithelial lining fluid, with a correlation whose slope suggested that the level of drug penetration into the lining fluid was 0.2. Concentrations of the antibiotic in cells recovered by bronchoalveolar lavage (21 +/- 10 micrograms/ml) were 2 and 10 times higher than in plasma (11.4 +/- 5.7 micrograms/ml) and epithelial lining fluid (2.0 +/- 1.7 micrograms/ml), respectively. Thus, when administered perorally in humans, roxithromycin is markedly accumulated by resident alveolar macrophages in concentrations largely exceeding the MBCs of the drug for most facultative intracellular pathogens including Legionella pneumophila, despite low concentrations in the epithelial lining fluid.
Chastre
J
J
Service de Reanimation Medicale, Hopital Bichat, Paris, France.
Brun
P
P
Fourtillan
J B
JB
Soler
P
P
Basset
G
G
Manuel
C
C
Trouillet
J L
JL
Gibert
C
C
D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism; D001992:Bronchoalveolar Lavage Fluid / Q000378:metabolism; D002908:Chronic Disease; D004848:Epithelium / Q000378:metabolism; D006801:Humans; D007933:Leucomycins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008168:Lung / Q000378:metabolism*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000378:metabolism
D007933:Leucomycins